|   | 
                  
                       | 
                      | 
                    
                        
                            
                                | 
                                  
                                 | 
                             
                             |  
                            
                                
                                    
                                        
  
    
	  | 
   
  
    
        
          |   | 
          
              
                | 
                    ÆÄ¶ó°ÔÁ÷Á¤  Paragesic Tab.  
                    
                 | 
               
              
                | 
                     ÀϹÝÀǾàǰ | ºñ±Þ¿©  
                        
                    	
                    
                 | 
               
              
                | 
					  
                  
				  
                 | 
               
              
              
              
              
              |   |  
              
                
                    
                        | 
                      ¾Ë¸²:  | 
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. | 
                     
                    | 
               
            
              
                
                   
                   
                   
                   
		   
                 | 
               
              
                | 
                  
                  
                 | 
               
              | 
            | 
         
       
       | 
   
    |  
  
    | 
      
     | 
     
  |                   
                                        | 
                                             | 
                                         
                            
                                
                            
                            
                              
                                                        
                              
                                                
                            
 |   
    | 
      
     | 
 
 |  
    
   
    | 
       
        À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
        ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
        ·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
       
     | 
   
  
     | 
   
  
  
    
      
  
    
       |  
      
        
          
            
                | Çã°¡Á¤º¸ | 
             
           
         | 
       
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
  
  
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× | 
    
      
      
            ºñ±Þ¿©
          
        
      
    
    
    
      
     [»óº´ÄÚµåÁ¶È¸]
      
      [Áúº´ÄÚµåÁ¶È¸]
     
     | 
   
   
    | ºü¸¥Á¶È¸ | 
    
      
     |   
   
  
  
  
   
    | Á¦Ç°¼º»ó | 
    Èò»ö¿øÇü Á¤Á¦
  [Á¦ÇüÁ¤º¸ È®ÀÎ] |   
   
  
  
  
  
  
   
    | Æ÷À塤À¯Åë´ÜÀ§ | 
    100Á¤/º´, 1000Á¤/º´ | 
   
  
  
  
  
  
  
  
 
  
  
    
  
  
  
  
  
  
  
  
  
  
 
  
  
  
 
  
  
  
  
  
  
   
    | Çã°¡»çÇ× ¿ø¹®Á¶È¸ | 
    
      
	    [Çã°¡»çÇ× ¿ø¹®Á¶È¸] 
     | 
   
  
  
  
  
     
  
  
  
   
    | È¿´ÉÈ¿°ú | 
    
    [ÀûÀÀÁõ º° °Ë»ö] 
      
    
     
	 
      (1) ¸¸¼º¿äÅë, ¿°Á ¹× ±äÀå, Å»Ãß·Î ÀÎÇÑ µð½ºÅ©, ¼±À¯¼º °áÇÕ±Ù¼Õ»ó, ºñ°üÀý¼º ·ù¸¶Æ¼½º(±Ù¿°, ±ÙÅë, ¼±À¯¼º °áÇÕÁ÷¿°), whipplash ¼Õ»ó ±Þ¼º»ç°æ, µÎÅë, ¿ù°æºÒ¼ø ¹× ±âŸ ±Þ¼º ¶Ç´Â ¸¸¼º ±ÙÀ°Åë°ú °ü·ÃµÈ °ñ°Ý±ÙÅëÀ¸·Î ÀÎÇÑ °æ·ÃÀÇ ¿ÏÈ¿¡ »ç¿ëµÈ´Ù. 
(2) ±¸¿¬»ê ¿ÃÆä³ªµå¸°Àº ÁßÃßÀûÀ¸·Î ÀÛ¿ëÇϸç Ç×»ó ÃËÁøÀÛ¿ëÀ» ¾ïÁ¦ÇÑ´Ù. Áï ¿¹¸¦ µé¸é °æ·Ã, °æÁ÷ ¶Ç´Â ±Ù°æ·Ãµî°ú °°ÀÌ °úµµÇÑ ÀÛ¿ëÀ¸·Î ÀÎÇÏ¿© ¾ß±âµÇ´Â ¿îµ¿ ½Å°æÀÛ¿ëÀÌ °íÁ¶µÇ´Â Çö»óÀ» ¼±ÅÃÀûÀ¸·Î ¾ïÁ¦½ÃŲ´Ù. 
(3) ±¸¿¬»ê ¿ÃÆä³ªµå¸°Àº ´Ù¸¸ Á¤»óÀûÀÎ ±ÙÀ°»óÅ ¶Ç´Â ÀÚü¿îµ¿±â´É¿¡ À§Çظ¦ ³¢Ä§ÀÌ ¾øÀÌ ±Ù°æ·Ã¿¡¸¸ ÀÌ¿ÏÀÛ¿ëÀ» ÇÑ´Ù. ±× ÀÛ¿ëÀº ½Å¼ÓÇÏ°í ºñ±³Àû Áö¼Ó½Ã°£ÀÌ ±æ´Ù. °ñ°Ý±Ù °æ·Ã¿¡ ´ëÇÑ È¿°ú´Â Electromyocrapy·Î °´°üÀûÀ¸·Î ÀÔÁõµÇ¾ú´Ù. 
(4) ¾Æ¼¼Æ® ¾Æ¹Ì³ëÆæÀº ¿ì¼öÇÑ ³»¼ºÀÌ ÁÁÀº ÇØ¿, ÁøÅëÁ¦ÀÌ´Ù. 
±× ÁøÅëÀÛ¿ëÀº ½Å¼ÓÇϰí(30ºÐ À̳» ±×¸®°í 3-4½Ã°£ Áö¼ÓÇÑ´Ù) 
±× ÀÛ¿ëÀº ±ÙÀ° ¹× ±× Á¢ÇÕºÎÀÇ ÅëÁõÀ» À̿ϽÃŰ´Â È¿°ú°¡ Å©´Ù. À§ÀåÀåÇØ¸¦ ÀÏÀ¸Å°°Å³ª ÃâÇ÷À» ¾ß±â½ÃŰÁö ¾Æ´ÏÇÑ´Ù. 
¾Æ¼¼Æ® ¾Æ¹Ì³ëÆæÀº ÃÖ¼Ò·®À» ÃʰúÇÏ¿© ´Ù·®À» º¹¿ëÇÏ´Â °æ¿ì´Â °£ ¶Ç´Â ½ÅÀåÀÇ ±«»ç Çö»óÀ» ¾ß±â½ÃŲ´Ù. 
      
     | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
    
  
  
   
    | ¾à¹°À½½Ä°£ »óÈ£ÀÛ¿ë | 
    
      
        [Á¶È¸]
     | 
   
  
  
  
  
   
    | ¿ë¹ý¿ë·® | 
    
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù. 
    
     
      
      
      [󹿾à¾î] 
      ¼ºÀÎÀÇ °æ¿ì 1ÀÏ 3ȸ, 1ȸ 2Á¤ 
12¼¼ ÀÌÇÏÀÇ ¾î¸°ÀÌ¿¡°Ô´Â º¹¿ë½ÃŰÁö ¸» °Í.     
      	
     | 
   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
   
    | ±Ý±â | 
    ±Ý±â 
±Ý±âÇö»óÀº ±¸¿¬»ê ¿ÃÆä³ªµå¸°ÀÇ ºÎ±³°¨½Å°æ¾ïÁ¦ ÀÛ¿ëÀ¸·Î ÀÎÇÏ¿© ³ªÅ¸³´Ù. ±×·¯¹Ç·Î ÀÌ ¾àÀº ³ì³»Àå, ¹è´¢°ï¶õ(¿¹ : Àü¸³¼±ÀÇ À§Ãà ȤÀº ¹æ±¤ÀÇ ±â´ÉÀå¾Ö·Î ÀÎÇÑ ¹è´¢°ï¶õÁõ, ±Ù¹«·ÂÁõ ȯÀÚ¿¡°Ô´Â Åõ¿©ÇÏ¿©¼´Â ¾ÈµÈ´Ù.) ¶ÇÇÑ ½É°èÇ×Áø ȯÀÚ¿¡°Ô´Â Á¶½ÉÇÏ¿© »ç¿ëÇÏ¿©¾ß ÇÑ´Ù. 
 
´ÙÀ½ ȯÀÚ¿¡´Â Åõ¿©ÇÏÁö ¸» °Í. 
1) Áö±Ý±îÁö ÀÌ ¾à¿¡ ÀÇÇÑ °ú¹ÎÁõ»ó(¿¹¸¦ µé¸é, ¹ßÁø, ¹ßÀû, °¡·Á¿ò, ºÎÁ¾(ÈĵÎ, ´«²¨Ç®, ÀÔ¼ú µî))À» ÀÏÀ¸Å² ÀûÀÌ ÀÖ´Â »ç¶÷ 
2) Áö±Ý±îÁö ÀÌ ¾à ¶Ç´Â ´Ù¸¥ °¨±â¾à, ÇØ¿ÁøÅëÁ¦¸¦ »ç¿ëÇÏ¿© õ½ÄÀÌ ³ªÅ¸³ ÀûÀÌ ÀÖ´Â »ç¶÷ 
3) ÀÌ ¾àÀº À¯´çÀ» ÇÔÀ¯Çϰí ÀÖÀ¸¹Ç·Î, °¥¶ôÅä¿À½º ºÒ³»¼º(galactose intolerace), Lapp À¯´çºÐÇØÈ¿¼Ò °áÇÌÁõ(Lapp lactase deficiency) ¶Ç´Â Æ÷µµ´ç-°¥¶ôÅä¿À½º Èí¼öÀå¾Ö(glucwse-galactose malabsorption) µîÀÇ À¯ÀüÀûÀÎ ¹®Á¦°¡ Àִ ȯÀÚ¿¡°Ô´Â Åõ¿©ÇÏ¸é ¾È µÈ´Ù.  | 
   
  
  
  
  
    
  
  
  
  
  
   
    | ÀÌ»ó¹ÝÀÀ | 
    
       ¾à°£ÀÇ È¯ÀÚÁß¿¡´Â ±¸¿¬»ê ¿ÃÆä³ªµå¸°µîÀ¸·Î ÀÎÇÏ¿© ºÎ±³°¨½Å°æ¿¡ ¹Î°¨ÇÑ È¯ÀÚ¿¡°Ô ±¸°¥, ±¸Åä, ½Ã·ÂÀÌ È帮°í ÇöÈÆ, ºÒ¾ÈµîÀÌ ÀϾ ¼ö°¡ ÀÖ´Ù. ÀÌ·¯ÇÑ Áõ»óÀº Åõ¿©·®À» °¨¼Ò½ÃŰ°Å³ª Áß´ÜÇÏ¸é ½Å¼ÓÈ÷ ÇØ¼ÒµÈ´Ù. 
 
º¹¿ë½Ã ÁÖÀÇ»çÇ× 
1) ÀÌ ¾àÀÇ º¹¿ë¿¡ ÀÇÇØ µå¹°°Ô ´ÙÀ½°ú °°Àº Áõ»óÀÌ ³ªÅ¸³µ´Ù°í º¸°íµÇ¾î ÀÖÀ¸¹Ç·Î ÀÌ¿Í °°Àº Áõ»óÀÌ ³ªÅ¸³ °æ¿ì¿¡´Â Áï½Ã º¹¿ëÀ» ÁßÁöÇϰí ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇÒ °Í. 
¨ç ÀÌ ¾àÀÇ º¹¿ë ÈÄ °ð¹Ù·Î µÎµå·¯±â, ºÎÁ¾(ÈĵÎ, ´«²¨Ç®, ÀÔ¼ú µî), °¡½¿´ä´äÇÔ µî°ú ÇÔ²² ¾È»öÀÌ Ã¢¹éÇØÁö°í, ¼öÁ·ÀÌ Â÷°¡¿ÍÁö°í, ½ÄÀº¶¡, ¼û°¡»Ý µîÀÌ ³ªÅ¸³ª´Â °æ¿ì 
¨è °í¿À» ¼ö¹ÝÇÏ¸ç ¹ßÁø, ¹ßÀû, È»ó¸ð¾ç ¼öÆ÷ µîÀÇ °Ý·ÄÇÑ Áõ»óÀÌ Àü½ÅÇǺÎ, ÀÔ ¹× ´«ÀÇ Á¡¸·¿¡ ³ªÅ¸³ °æ¿ì 
¨é õ½ÄÀÌ ³ªÅ¸³ °æ¿ì 
2) ¹Ù¸£ºñÅ»°è ¾à¹°, »ïȯ°è Ç׿ì¿ïÁ¦ ¹× ¾ËÄÚ¿ÃÀ» Åõ¿©ÇÑ È¯ÀÚ´Â ´Ù·®ÀÇ ¾Æ¼¼Æ®¾Æ¹Ì³ëÆæÀ» ´ë»ç½ÃŰ´Â ´É·ÂÀÌ °¨¼ÒµÇ¾î ¾Æ¼¼Æ®¾Æ¹Ì³ëÆæÀÇ Ç÷Àå ¹Ý°¨±â¸¦ Áõ°¡½Ãų ¼ö ÀÖ´Ù. ¾ËÄÚ¿ÃÀº ¾Æ¼¼Æ®¾Æ¹Ì³ëÆæ °ú·®Åõ¿©ÀÇ °£µ¶¼ºÀ» Áõ°¡½Ãų ¼ö ÀÖ´Ù. 
      
     | 
   
        
  
  
  
    
  
  
       	
  
     
  
  
  
  
  
   
    | Related FDA Approved Drug | 
    
      
      ±âÁØ ¼ººÐ: ORPHENADRINE CITRATEINVAGESIC (ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE) 
INVAGESIC FORTE (ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE) 
NORFLEX (ORPHENADRINE CITRATE) 
NORGESIC (ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE) 
NORGESIC FORTE (ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE) 
ORPHENADRINE CITRATE (ORPHENADRINE CITRATE) 
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE (ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE) 
ORPHENGESIC (ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE) 
ORPHENGESIC FORTE (ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE) 
±âÁØ ¼ººÐ: ACETAMINOPHENACEPHEN (ACETAMINOPHEN) 
ACETAMINOPHEN (ACETAMINOPHEN) 
ACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN; CODEINE PHOSPHATE) 
ACETAMINOPHEN AND HYDROCODONE BITARTRATE (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE (ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE) 
ACETAMINOPHEN, ASPIRIN AND CAFFEINE (ACETAMINOPHEN; ASPIRIN; CAFFEINE) 
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE (ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE) 
ACETAMINOPHEN, BUTALBITAL AND CAFFEINE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE) 
ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE (ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE) 
ALLAY (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
ANEXSIA (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
ANEXSIA 5/325 (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
ANEXSIA 7.5/325 (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
ANEXSIA 7.5/650 (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
ANOQUAN (ACETAMINOPHEN; BUTALBITAL; CAFFEINE) 
BANCAP (ACETAMINOPHEN; BUTALBITAL) 
BANCAP HC (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
BUCET (ACETAMINOPHEN; BUTALBITAL) 
BUTALBITAL ACETAMINOPHEN AND CAFFEINE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE) 
BUTALBITAL AND ACETAMINOPHEN (ACETAMINOPHEN; BUTALBITAL) 
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE) 
BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE WITH CODEINE PHOSPHATE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE) 
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE) 
BUTALBITAL; ACETAMINOPHEN; CAFFEINE; CODEINE (BUTALBITAL; ACETAMINOPHEN; CAFFEINE; CODEINE PHOSPHATE) 
BUTAPAP (ACETAMINOPHEN; BUTALBITAL) 
CAPITAL AND CODEINE (ACETAMINOPHEN; CODEINE PHOSPHATE) 
CODEINE, ASPIRIN, APAP FORMULA NO. 2 (ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE) 
CODEINE, ASPIRIN, APAP FORMULA NO. 3 (ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE) 
CODEINE, ASPIRIN, APAP FORMULA NO. 4 (ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE) 
CODRIX (ACETAMINOPHEN; CODEINE PHOSPHATE) 
CO-GESIC (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
DARVOCET (ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE) 
DARVOCET A500 (ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE) 
DARVOCET-N 100 (ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE) 
DARVOCET-N 50 (ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE) 
DHC PLUS (ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE) 
DOLENE AP-65 (ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE) 
DRIXORAL PLUS (ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE) 
DURADYNE DHC (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
EMPRACET W/ CODEINE PHOSPHATE #3 (ACETAMINOPHEN; CODEINE PHOSPHATE) 
EMPRACET W/ CODEINE PHOSPHATE #4 (ACETAMINOPHEN; CODEINE PHOSPHATE) 
ESGIC (ACETAMINOPHEN; BUTALBITAL; CAFFEINE) 
ESGIC-PLUS (ACETAMINOPHEN; BUTALBITAL; CAFFEINE) 
EXCEDRIN (MIGRAINE) (ACETAMINOPHEN; ASPIRIN; CAFFEINE) 
FEMCET (ACETAMINOPHEN; BUTALBITAL; CAFFEINE) 
FIORICET (ACETAMINOPHEN; BUTALBITAL; CAFFEINE) 
FIORICET W/ CODEINE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE) 
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
HY-PHEN (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
INFANTS' FEVERALL (ACETAMINOPHEN) 
INJECTAPAP (ACETAMINOPHEN) 
LORCET-HD (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
LORTAB (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
MEDIGESIC PLUS (ACETAMINOPHEN; BUTALBITAL; CAFFEINE) 
NEOPAP (ACETAMINOPHEN) 
NORCET (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
NORCO (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
OXYCET (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE) 
OXYCODONE 2.5/APAP 500 (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE) 
OXYCODONE 5/APAP 500 (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE) 
OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE) 
PAPA-DEINE #3 (ACETAMINOPHEN; CODEINE PHOSPHATE) 
PAPA-DEINE #4 (ACETAMINOPHEN; CODEINE PHOSPHATE) 
PERCOCET (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE) 
PHENAPHEN W/ CODEINE NO. 2 (ACETAMINOPHEN; CODEINE PHOSPHATE) 
PHENAPHEN W/ CODEINE NO. 3 (ACETAMINOPHEN; CODEINE PHOSPHATE) 
PHENAPHEN W/ CODEINE NO. 4 (ACETAMINOPHEN; CODEINE PHOSPHATE) 
PHENAPHEN-650 W/ CODEINE (ACETAMINOPHEN; CODEINE PHOSPHATE) 
PHRENILIN (ACETAMINOPHEN; BUTALBITAL) 
PHRENILIN FORTE (ACETAMINOPHEN; BUTALBITAL) 
PHRENILIN WITH CAFFEINE AND CODEINE (ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE) 
PROPACET 100 (ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE) 
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN (ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE) 
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN (ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE) 
PROVAL #3 (ACETAMINOPHEN; CODEINE PHOSPHATE) 
ROXICET (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE) 
ROXICET 5/500 (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE) 
ROXILOX (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE) 
SEDAPAP (ACETAMINOPHEN; BUTALBITAL) 
SYNALGOS-DC-A (ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE) 
TALACEN (ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE) 
TAVIST ALLERGY/SINUS/HEADACHE (ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE) 
TENCON (ACETAMINOPHEN; BUTALBITAL) 
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN (ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE) 
TRIAD (ACETAMINOPHEN; BUTALBITAL; CAFFEINE) 
TRIAPRIN (ACETAMINOPHEN; BUTALBITAL) 
TYCOLET (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
TYLENOL (ACETAMINOPHEN) 
TYLENOL (CAPLET) (ACETAMINOPHEN) 
TYLENOL (GELTAB) (ACETAMINOPHEN) 
TYLENOL W/ CODEINE (ACETAMINOPHEN; CODEINE PHOSPHATE) 
TYLENOL W/ CODEINE NO. 1 (ACETAMINOPHEN; CODEINE PHOSPHATE) 
TYLENOL W/ CODEINE NO. 2 (ACETAMINOPHEN; CODEINE PHOSPHATE) 
TYLENOL W/ CODEINE NO. 3 (ACETAMINOPHEN; CODEINE PHOSPHATE) 
TYLENOL W/ CODEINE NO. 4 (ACETAMINOPHEN; CODEINE PHOSPHATE) 
TYLOX (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE) 
TYLOX-325 (ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE) 
ULTRACET (ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE) 
VICODIN (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
VICODIN ES (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
VICODIN HP (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
WYGESIC (ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE) 
ZYDONE (ACETAMINOPHEN; HYDROCODONE BITARTRATE) 
        
     | 
      
  
  
  |  
     
   
  
    
       |  
      
        
          
            
                | Á¤º¸¿ä¾à |         
             
           
         | 
             	    
       |  
      | 
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
    
  
  
    
  
   |  
     
   
  
    
       |  
      
        
          
            
                | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |         
             
           
         | 
             	    
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
  
  
  
  
  
  
  
  
  	
   
    | ´ëÇ¥ÄÚµå | 
    8806448027201 | 
   
  
  
  
  
   
    | BIT ¾àÈ¿ºÐ·ù | 
    
      ±âŸ ÁøÅëÁ¦ (Other Analgesics & Antipyretics)
     | 
   
  
  
  
   
    | ATC ÄÚµå | 
    Orphenadrine, combinations  / M03BC51
     
      [ÄÚµåºÐ·ù»ó¼¼¼³¸í]
      
        [ATCÄÚµå¿¹Ãø]
      
     | 
   
  
  
  
  
  
  
  
 
  
  
   
    | º¹ÁöºÎºÐ·ùÄÚµå | 
    
    114  (ÇØ¿¡¤ÁøÅ롤¼Ò¿°Á¦                                              )
      
     | 
   
  
  
  
  
  
  
   
  
     
  
  
  
  
   
    | Drugs By Indication | 
    
      [Àüüº¸±â]
     | 
   
  
   
    | Drugs By Classification | 
    
      [Àüüº¸±â]
     | 
     
 	 |  
     
   
  
    
       |  
      
        
          
            
                | Á¦Ç°Á¤º¸ |            
             
           
         | 
             	  
       |  
       |  
     
   
  
    
       |  
      
        
          
            
                | º¹¾àÁ¤º¸ |            
             
           
         | 
             	  
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
   
    | LACTmed ¹Ù·Î°¡±â | 
    
      
        [¹Ù·Î°¡±â]
     | 
     
  
  
   
    | ¾à¸®ÀÛ¿ë | 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
       
     | 
     
  
  
       
  
  
   
    | º¹¾àÁöµµ | 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù.
    
     | 
   
                                                          															
  
   
  
  
   
    | ÀӺο¡´ëÇÑÅõ¿© | 
    
      
      
        
	      
	      
	        | *  | 
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	         | 
	         
	       
	       | 
	   
	  
	    |   | 
	   
	  
	    
	      FDA : Cµî±Þ 
				        
				         (orphenadrine )
				        
	   | 
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   | 
	 
	
	  
	      
	      
	        | *  | 
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
	         | 
	         
	      
	        | *  | 
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
	         | 
	         
	       
	   | 
	 
       
     | 
   
  
  
  	   
  
  	   
  
  	   
  
  
     
      | Pharmacokinetics | 
      
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù.
      
       |   
     
  
  
  
  
  
  
  
   
    | º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ | 
    
      [º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
     | 
   
  	
  
  
  	
  
  
  
   
    | º¸°ü»ó ÁÖÀÇ | 
    
      
    	
     | 
   
  
  
   
    | Á¶Á¦½Ã ÁÖÀÇ | 
    
      
    	
     | 
      
 
 |  
     
   
  
    
       |  
      
        
          
            
                | ½É»çÁ¤º¸ |            
             
           
         | 
             	  
       |  
       |  
     
     
  
    
       |  
      
        
          
            
                | ÇмúÁ¤º¸ |          
             
           
         | 
             	  
       |  
      
  
    | Ç׸ñ | 
    ³»¿ë | 
   
  
    | DUR (ÀǾàǰ»ç¿ëÆò°¡) | 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	  [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
       [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
       
       
        
        
     | 
   
  
   
    | µ¶¼ºÁ¤º¸ | 
    Acetaminophen¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â 
  Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do  | 
   
  
   
    | Mechanism of Action | 
    
       Acetaminophen¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Acetaminophen is thought to act primarily in the CNS, increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1 and COX-2, enzymes involved in prostaglandin (PG) synthesis. Unlike NSAIDs, acetaminophen does not inhibit cyclooxygenase in peripheral tissues and, thus, has no peripheral anti-inflammatory affects. While aspirin acts as an irreversible inhibitor of COX and directly blocks the enzyme's active site, studies have found that acetaminophen indirectly blocks COX, and that this blockade is ineffective in the presence of peroxides. This might explain why acetaminophen is effective in the central nervous system and in endothelial cells but not in platelets and immune cells which have high levels of peroxides. Studies also report data suggesting that acetaminophen selectively blocks a variant of the COX enzyme that is different from the known variants COX-1 and COX-2. This enzyme is now referred to as COX-3. Its exact mechanism of action is still poorly understood, but future research may provide further insight into how it works.
  Orphenadrine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Orphenadrine binds to both histamine H1 receptors and NMDA receptors. It restores the motor disturbances induced by neuroleptics, in particular the hyperkinesia. The dopamine deficiency in the striatum increases the stimulating effects of the cholinergic system. This stimulation is counteracted by the anticholinergic effect of orphenadrine. It may have a relaxing effect on skeletal muscle spasms and it has a mood elevating effect. 
     | 
   
  
   
    | Pharmacology | 
     
       Acetaminophen¿¡ ´ëÇÑ Pharmacology Á¤º¸ Acetaminophen (USAN) or Paracetamol (INN) is a popular analgesic and antipyretic drug that is used for the relief of fever, headaches, and other minor aches and pains. It is a major ingredient in numerous cold and flu medications and many prescription analgesics. It is extremely safe in standard doses, but because of its wide availability, deliberate or accidental overdoses are not uncommon. Acetaminophen, unlike other common analgesics such as aspirin and ibuprofen, has no anti-inflammatory properties or effects on platelet function, and so it is not a member of the class of drugs known as non-steroidal anti-inflammatory drugs or NSAIDs. In normal doses acetaminophen does not irritate the lining of the stomach nor affect blood coagulation, the kidneys, or the fetal ductus arteriosus (as NSAIDs can). Like NSAIDs and unlike opioid analgesics, acetaminophen does not cause euphoria or alter mood in any way. Acetaminophen and NSAIDs have the benefit of being completely free of problems with addiction, dependence, tolerance and withdrawal. Acetaminophen is used on its own or in combination with pseudoephedrine, dextromethorphan, chlorpheniramine, diphenhydramine, doxylamine, codeine, hydrocodone, or oxycodone.
  Orphenadrine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Orphenadrine is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. Orphenadrine is an anticholinergic with a predominantly central effect and only a weak peripheral effect. In addition, it has mild antihistaminic and local anaesthetic properties. Parkinson's syndrome is the consequence of a disturbed balance between cholinergic and dopaminergic neurotransmission in the basal ganglia caused by a decrease in dopamine. Orphenadrine restores the physiological equilibrium and has a favourable effect on the rigidity and tremor of Parkinson's disease and Parkinsonian syndromes. The effect is somewhat less on bradykinesia. 
     | 
   
  
   
    | Metabolism | 
    
       Acetaminophen¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 1A2 (CYP1A2)Cytochrome P450 2E1 (CYP2E1)
  Orphenadrine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2B6 (CYP2B6)Cytochrome P450 2E1 (CYP2E1) 
     | 
   
  
   
    | Protein Binding | 
    
       Orphenadrine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 95% 
     | 
   
  
   
    | Half-life | 
    
       Acetaminophen¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 1 to 4 hours
  Orphenadrine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 13-20 hours 
     | 
   
  
   
    | Absorption | 
    
       Acetaminophen¿¡ ´ëÇÑ Absorption Á¤º¸ Rapid and almost complete
  Orphenadrine¿¡ ´ëÇÑ Absorption Á¤º¸ Orphenadrine is almost completely absorbed in the gastrointestinal tract. 
     | 
   
  
   
    | Pharmacokinetics | 
    
       Orphenadrine CitrateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
- ÃÖ´ëÈ¿°ú ¹ßÇö½Ã°£ : °æ±¸ : 2-4 ½Ã°£ À̳»
 - ÀÛ¿ëÁö¼Ó½Ã°£ : 4-6 ½Ã°£
 - ´Ü¹é°áÇÕ : 20%
 - ´ë»ç : ´ëºÎºÐ ´ë»çµÊ
 - ¹Ý°¨±â : 14-16 ½Ã°£
 - ¼Ò½Ç : ÁÖ·Î ½Å¹è¼³ (8%´Â ¹Ìº¯Èü·Î)
  
 AcetaminophenÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á 
	- ´Ü¹é°áÇÕ : 20-50%
	
 - ´ë»ç : 
	
 - »ó¿ë·®¿¡¼ : °£¿¡¼ sulfate¿Í glucuronide Æ÷ÇÕü·Î ´ë»çµÇ¸ç, ¼Ò·®Àº microsomal mixed function oxidases¿¡ ÀÇÇØ ¹ÝÀÀ¼ºÀÌ ¸Å¿ì ³ôÀº Áß°£´ë»çü(acetylimidoquinone)·Î ´ë»çµÈ ÈÄ glutathione Æ÷ÇÕÀ¸·Î ºñȰ¼ºÈµÈ´Ù. 
	
 - Áßµ¶·®¿¡¼ (4gÀ» ´Ü ÇÏ·ç º¹¿ëÇÑ Á¤µµ±îÁöµµ Æ÷ÇԵȴÙ) : glutathione Æ÷ÇÕÀÌ Á¡Á¡ ºÒÃæºÐÇÏ°Ô µÇ¾î 		acetylimidoquinone ³óµµ°¡ Áõ°¡ÇÏ°Ô µÇ¸ç À̰ÍÀÌ °£¼¼Æ÷ ±«»ç¸¦ À¯¹ßÇÏ´Â °ÍÀ¸·Î ¿©°ÜÁö°í ÀÖ´Ù. 
	
 - ¹Ý°¨±â
	
		- ½Å»ý¾Æ : 2-5 ½Ã°£  
		
 - ¼ºÀÎ
		
			- Á¤»ó ½Å±â´É : 1-3 ½Ã°£	
			
 - ¸»±â ½ÅÁúȯ : 1-3 ½Ã°£
		
  
	  
	 - ÃÖ´ëÇ÷Áß³óµµ µµ´Þ½Ã°£
	
		- °æ±¸ : »ó¿ë·® º¹¿ë½Ã 10-60ºÐ, ±Þ¼º Áßµ¶·® º¹¿ë½Ã Áö¿¬µÉ ¼ö ÀÖ´Ù.
	
  
  
     | 
   
  
   
    | Biotransformation | 
    
       Acetaminophen¿¡ ´ëÇÑ Biotransformation Á¤º¸ Approximately 90 to 95% of a dose is metabolized in the liver via the cytochrome P450 enzyme pathways (primarily by conjugation with glucuronic acid, sulfuric acid, and cysteine). An intermediate metabolite is hepatotoxic and most likely nephrotoxic and can accumulate after the primary metabolic pathways have been saturated.
  Orphenadrine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Biotransformation occurs mainly in the liver. Pharmacologically active metabolites are N-demethyl orphenadrine and N,N-didemethyl orphenadrine. 
     | 
   
  
   
    | Toxicity | 
    
       Acetaminophen¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral, mouse: LD50 = 338 mg/kg; Oral, rat: LD50 = 1944 mg/kg. Acetaminophen is metabolized primarily in the liver, where most of it is converted to inactive compounds by conjugation with sulfate and glucuronide, and then excreted by the kidneys. Only a small portion is metabolized via the hepatic cytochrome P450 enzyme system. The toxic effects of acetaminophen are due to a minor alkylating metabolite (N-acetyl-p-benzo-quinone imine), not acetaminophen itself nor any of the major metabolites. This toxic metabolite reacts with sulfhydryl groups. At usual doses, it is quickly detoxified by combining irreversibly with the sulfhydryl group of glutathione to produce a non-toxic conjugate that is eventually excreted by the kidneys. The toxic dose of paracetamol is highly variable. In adults, single doses above 10 grams or 140 mg/kg have a reasonable likelihood of causing toxicity. In adults, single doses of more than 25 grams have a high risk of lethality.
  Orphenadrine¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral, mouse LD50 = 100 mg/kg; oral, rat LD50 = 255 mg/kg 
     | 
   
  
   
    | Drug Interactions | 
    
       Acetaminophen¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Anisindione	Acetaminophen  increases the anticoagulant effectWarfarin	Acetaminophen increases the anticoagulant effectImatinib	Increased hepatic toxicity of both agentsIsoniazid	Risk of hepatotoxicityDicumarol	Acetaminophen increases the anticoagulant effectDicumarol	Increases the anticoagulant effectAcenocoumarol	Increases the anticoagulant effect
  Orphenadrine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Docetaxel	The agent increases the serum levels and toxicity of docetaxelDonepezil	Possible antagonism of actionGalantamine	Possible antagonism of actionRivastigmine	Possible antagonism of action 
     | 
   
  
   
    CYP450  Drug Interaction | 
    
      [CYP450 TableÁ÷Á¢Á¶È¸] Acetaminophen¿¡ ´ëÇÑ P450 table
  SUBSTRATES 
CYP 2E1 
**acetaminophen** 
chlorzoxazone 
ethanol 
 INHIBITORS 
CYP 2E1 
disulfiram 
 INDUCERS 
CYP 2E1 
ethanol 
isoniazid 
 
     | 
   
  
   
    | Food Interaction | 
    
       Acetaminophen¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take without regard to meals.Avoid alcohol (may increase risk of hepatotoxicity).
  Orphenadrine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take without regard to meals. Avoid alcohol. 
     | 
   
  
   
    | Drug Target | 
    
      
      [Drug Target]
     | 
   
  
   
    | Description | 
    
       Acetaminophen¿¡ ´ëÇÑ Description Á¤º¸ Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage. [PubChem]
  Orphenadrine¿¡ ´ëÇÑ Description Á¤º¸ A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. [PubChem] 
     | 
   
  
   
    | Dosage Form | 
    
       Acetaminophen¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule	OralElixir	OralLiquid	OralSolution	OralSolution / drops	OralSuppository	RectalSuspension	OralSyrup	OralTablet	OralTablet, effervescent	OralTablet, extended release	Oral
  Orphenadrine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid	IntravenousTablet	OralTablet, extended release	Oral 
     | 
   
  
   
    | Drug Category | 
    
       Acetaminophen¿¡ ´ëÇÑ Drug_Category Á¤º¸ Analgesics, Non-NarcoticAntipyretics
  Orphenadrine¿¡ ´ëÇÑ Drug_Category Á¤º¸ AntidyskineticsAntiparkinson AgentsMuscarinic AntagonistsMuscle Relaxants, CentralParasympatholyticsSkeletal Muscle Relaxants 
     | 
   
  
   
    | Smiles String Canonical | 
    
       Acetaminophen¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(=O)NC1=CC=C(O)C=C1
  Orphenadrine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1C 
     | 
   
  
   
    | Smiles String Isomeric | 
    
       Acetaminophen¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC(=O)NC1=CC=C(O)C=C1
  Orphenadrine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN(C)CCO[C@@H](C1=CC=CC=C1)C1=CC=CC=C1C 
     | 
   
  
   
    | InChI Identifier | 
    
       Acetaminophen¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)/f/h9H
  Orphenadrine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3 
     | 
   
  
   
    | Chemical IUPAC Name | 
    
       Acetaminophen¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ N-(4-hydroxyphenyl)acetamide
  Orphenadrine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ N,N-dimethyl-2-[(2-methylphenyl)-phenylmethoxy]ethanamine 
     | 
   
  
   
    | Drug-Induced Toxicity Related Proteins | 
    
      ACETAMINOPHEN ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Alpha-2A adrenergic receptor  Drug:acetaminophen Toxicity:hepatic injury .  [¹Ù·Î°¡±â] Replated Protein:Myeloperoxidase  Drug:acetaminophen Toxicity:respiratory burst.  [¹Ù·Î°¡±â] Replated Protein:Glucose-6-phosphate 1-dehydrogenase Drug:acetaminophen Toxicity:drug-induced hemolysis.  [¹Ù·Î°¡±â] Replated Protein:Ornithine decarboxylase Drug:acetaminophen Toxicity:hepatotoxicity.  [¹Ù·Î°¡±â] Replated Protein:Lactate dehydrogenase Drug:acetaminophen Toxicity:hepatotoxicity.  [¹Ù·Î°¡±â] Replated Protein:Transcription factor AP-1(JUN) Drug:acetaminophen Toxicity:hepatotoxicity.  [¹Ù·Î°¡±â] Replated Protein:Haptoglobin  Drug:acetaminophen Toxicity:drug-induced hemolysis.  [¹Ù·Î°¡±â] Replated Protein:Alanine aminotransferase Drug:acetaminophen Toxicity:hepatotoxicity.  [¹Ù·Î°¡±â] Replated Protein:Beta-glucuronidase  Drug:acetaminophen Toxicity:hepatotoxin-induced effects.  [¹Ù·Î°¡±â] Replated Protein:CYP2E1 Drug:Acetaminophen Toxicity:idiosyncratic hepatotoxicity.  [¹Ù·Î°¡±â] Replated Protein:Cytochrome P450 2E1  Drug:acetaminophen  Toxicity:hepatotoxicity.  [¹Ù·Î°¡±â] Replated Protein:Sulfotransferase family cytosolic Drug:acetaminophen  Toxicity:chronic hypoxia.  [¹Ù·Î°¡±â] Replated Protein:Cytochrome P450 3A4  Drug:acetaminophen  Toxicity:hepatotoxicity.  [¹Ù·Î°¡±â] Replated Protein:Caspase recruitment domain-containing protein  Drug:acetaminophen  Toxicity:hepatotoxicity.  [¹Ù·Î°¡±â] Replated Protein:Cytochrome P450 1A2  Drug:acetaminophen  Toxicity:hepatotoxicity.  [¹Ù·Î°¡±â] ACETAMINOPHEN (APAP) ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Cytochrome P450 Drug:acetaminophen (APAP) Toxicity:renal functional changes, strain-dependent histopathological changes.  [¹Ù·Î°¡±â] 
     | 
   
    
  |  
     
     
  
    
       |  
      
        
          
            
                | »ç¿ëÀÚÄÁÅÙÃ÷ |           
             
           
         | 
             	  
       |  
       |  
     
         
 
     | 
   
   
     | 
   
  
    
      
        
          
            
              - 
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-03-15
              
 
              - 
                
                 º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                
              
     
             
         |                 
       
     |       
          
                
                    
                       ¾Ë¸² | 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  | 
                    
                    | 
               
      
      
                
                    
                       °æ°í | 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 | 
  
                    | 
               
  
 
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
   
  
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
 
 |  
                           
                         | 
                       
                      | 
                   |